Sugi Predict

Sugi Predict / Compounds / Naphthalene

Naphthalene

Naphthalene

SCHEMBL2016036

N=S(=O)=O.c1ccc2ccccc2c1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 6/20 0.57
▸ ALOX12 P18054 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CES2 O00748 1/20 0.36
▸ CES1 P23141 1/20 0.36
▸ CYP1A2 P05177 2/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ GSTP1 P09211 1/20 0.35
▸ LMNA P02545 1/20 0.33
▸ AGXT P21549 1/20 0.33
▸ HPRT1 P00492 1/20 0.33
▸ F2 P00734 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naphthalene SCHEMBL27603103 0.97 CYP2A6 (0.53) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL27329954 0.85 CYP2A6 (0.67) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL28238017 0.79 CYP2A6 (0.57) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL8009302 0.76 CYP2A6 (0.53) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL15254628 0.76 CYP2A6 (0.53) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Biphenyl SCHEMBL15610556 0.76 ALDH1A1 (0.60) ALDH1A1HSD17B10TDP1TSHRCYP1A2
Naphthalene SCHEMBL15254629 0.76 CYP2A6 (0.53) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL8953 0.76 CYP2A6 (1.00) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL1332240 0.76 CYP2A6 (1.00) CYP2A6ALOX12ALDH1A1HSD17B10TDP1
Naphthalene SCHEMBL1330659 0.76 CYP2A6 (1.00) CYP2A6ALOX12ALDH1A1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109982695-A Immunomodulator 国立大学法人奈良先端科学技术大学院大学 2019-07-05 — — CN claimed
CN-108752245-A Naphthalene sulfonylamide acetamides and its application and pharmaceutical composition 宁夏医科大学 2018-11-06 — — CN claimed
US-20150038443-A1 Transcription Factor Inhibitors and Related Compositions, Formulations and Methods NATIONWIDE CHILDREN'S HOSPITAL, INC. (US) 2015-02-05 — — US claimed
US-8883749-B2 Transcription factor inhibitors and related compositions, formulations and methods THE OHIO STATE UNIVERSITY (US) 2014-11-11 — — US claimed
EP-2504000-A1 TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS The Ohio State University (US) 2012-10-03 — — EP claimed
US-20110212911-A1 TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS NIH - DEITR 2011-09-01 — — US claimed
WO-2011066263-A1 TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS THE OHIO STATE UNIVERSITY (US) 2011-06-03 — — WO claimed
CN-101273157-A Zinc-nickel alloy electroplating system PAVCO INC (US) 2008-09-24 — — CN claimed
CN-1585636-A Use of endothelin receptor antagonists in the treatment of tumour diseases MERCK PATENT GMBH (DE) 2005-02-23 — — CN claimed
CN-1141421-C Ductility agents for nickel-tungsten alloys OMI 2004-03-10 — — CN claimed
CN-1294642-A Ductility agents for nickel-tungsten alloys ENTHONE OMI INC (US) 2001-05-09 — — CN claimed
CN-1061652-C Endotheliomycine receptor antagonist MERCK PATENT GMBH (DE) 2001-02-07 — — CN claimed
CN-1141919-A Endotheliomycine receptor antagonist MOOK PATENT AG (DE) 1997-02-05 — — CN claimed
CN-108395372-B The metal complex and its synthetic method of double cup [4] arene derivatives and application 中国科学院苏州生物医学工程技术研究所 2019-09-10 — — CN disclosed
CN-109982695-A Immunomodulator 国立大学法人奈良先端科学技术大学院大学 2019-07-05 — — CN disclosed
CN-108314690-B The metal complex and its synthetic method of double cup [4] arene derivatives and application 中国科学院苏州生物医学工程技术研究所 2019-06-07 — — CN disclosed
CN-1074214-A The preparation method of isoquinoline sulfone amide derivative JOHNSON MATTHEY PLC (JP) 1993-07-14 — — CN disclosed
CN-1070910-A New thiazolyl benzofuran derivative, its preparation method and contain the pharmaceutical composition of this derivative FUJISAWA PHARMACEUTICAL CO (JP) 1993-04-14 — — CN disclosed
CN-1044098-A Compounds with vascular smooth muscle relaxing activity HIDAKA HIROYOSHI (JP) 1990-07-25 — — CN disclosed
CN-87103500-A ZINC-NICKEL ALLOYS ELECTROLYTE AND METHOD — 1987-12-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212911-A1 TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS STAT3, TCF12, STAT5A CYP2A6 4369/4885ALOX12 698/4885ALDH1A1 3193/4885
US-20150038443-A1 Transcription Factor Inhibitors and Related Compositions, Formulations and Methods STAT3, TCF12, STAT5A CYP2A6 4369/4885ALOX12 698/4885ALDH1A1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.